Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC
Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.
Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC
Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.